Formerly CEO of Isconova, which was acquired by Novavax last year
Novavax, a US-based clinical-stage biopharmaceutical company focused on the development of recombinant nanoparticle vaccines and adjuvants, has appointed Sven Andreasson as Senior Vice President, Corporate Development, effective from 2 June.
Andreasson has a long history of experience in biopharmaceutical operations, executive management and strategic development. From 2012 to 2013 he was Chief Executive of Isconova in Uppsala, Sweden, an international vaccine adjuvant company acquired by Novavax in 2013. Before that he was Chief Executive of Beta-Cell in Brussels, Belgium from 2008 to 2012 and Chief Executive of Active Biotech in Lund, Sweden from 1999 to 2008. He also spent a number of years at Pharmacia Corporation.